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Abstract: An imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs) may contribute to liver fibrosis in patients with hepatitis C (HCV)
infection. We measured the circulating levels of different MMPs and TIMPs in HCV monoinfected
and HIV/HCV coinfected patients and evaluated the potential for anti-HCV therapy to modulate
MMP and TIMP levels in HCV subjects. We analyzed 83 plasma samples from 16 HCV monoinfected
patients undergoing dual or triple anti-HCV therapy, 15 HIV/HCV coinfected patients with
undetectable HIV load, and 10 healthy donors (HD). Levels of MMP-1, MMP-2, MMP-3, MMP-8,
MMP-9, MMP-10, TIMP-1, and TIMP-2 were measured by a SearchLight Multiplex Immunoassay Kit.
MMP-2 and MMP-9 were the highest expressed MMPs among all the analyzed samples and their
levels significantly increased in HCV monoinfected and HIV/HCV coinfected subjects compared to
HD. TIMP-1 levels were significantly higher in HCV and HIV/HCV subjects compared to HD and
were correlated with liver stiffness. These findings raise the possibility of using circulating TIMP-1 as
a non-invasive marker of liver fibrosis in HCV infection. A longitudinal study demonstrated that
MMP-9 levels significantly decreased (40% reduction from baseline) in patients receiving dual as well
as triple direct-acting antivirals (DAA) anti-HCV therapy, which had no effect on MMP-2, TIMP-1,
and TIMP-2. As the dysregulation of MMP-2 and MMP-9 may reflect inflammatory processes in the
liver, the decrease of MMP-9 following HCV protease inhibitor treatment suggests a positive effect
on the reduction of liver inflammation.
Keywords: matrix metalloproteinases; tissue inhibitors of metalloproteinases; HIV/HCV coinfection;
liver fibrosis; anti-HCV therapy
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1. Introduction
Chronic infection with hepatitis C virus (HCV) is characterized by progressive damage to
liver tissue leading to progressive fibrosis and evolving ultimately to cirrhosis, liver failure, and
hepatocellular carcinoma [1]. Liver fibrosis is a dynamic pathologic process characterized by an
accumulation of the extracellular matrix, which is a consequence of an imbalance between the enhanced
matrix synthesis and reduced breakdown of connective tissue proteins reflecting dysregulation of
several pathways, including matrix metalloproteinases (MMPs) and their natural tissue inhibitors
(TIMPs) [2] MMPs are a large family of zinc-dependent endopeptidases that degrade the components of
extracellular matrix and basement membrane [3]. The activity of MMPs is highly regulated both at the
level of gene expression and by activation of latent pro-MMPs to active enzymes [4]. In the extracellular
milieu, the activity of these enzymes is controlled by TIMPs, which form stable, non-covalent complexes
with active MMPs [5]. Changes in the fine balance between MMPs and TIMPs drives the turnover of
the extracellular matrix and may be crucial for inflammation in infection as well as other pathological
conditions. With regard to HCV, several data in literature indicated that hepatic fibroproliferation has
been associated with alterations in the expression of circulating and hepatic MMPs and TIMPs [6–8],
but results obtained are controversial and the information is fragmentary as most studies are limited
to the analysis of individual MMPs and/or TIMPs.
In recent years HCV has emerged as an important opportunistic pathogen among patients with
HIV diseases [9] and infection with HIV appears to adversely affect the outcome of chronic HCV
hepatitis. A synergy between the two viruses leads to a higher rate of viral persistence, an increase of
viral load, higher rates of hepatic decompensation, and an increase in the likelihood of oncogenesis
with a faster rate of liver fibrosis progression [10]. Retrospective studies reported that coinfected
patients were more likely to develop severe liver fibrosis and cirrhosis [11,12], but the reasons for the
accelerated progression of hepatic fibrosis in HIV/HCV coinfected patients are not well elucidated.
Hence, advances in the understanding of the pathophysiology and regulation of fibrosis are
fundamental for the development of therapeutic strategies. Different data suggest that HIV suppression
achieved with antiretroviral therapy (ART) ameliorates HCV-related liver disease progression and
reduces liver-related mortality in HIV/HCV coinfected patients [13].
We have previously demonstrated that HIV/HCV coinfected subjects exhibit an altered balance
between circulating MMP-9 and TIMP-1 [14], probably due to the chronic state of immune activation
and cytokine dysregulation associated with HIV disease [15]. Although the effects of antiretroviral
therapy have been studied on some MMPs and TIMPs in the course of HIV/HCV coinfection, little is
known about the effect of antivirals in the course of HCV infection.
The current anti-HCV therapies are not designed to be anti-fibrotic but are focused on virus
eradication. For many years, treatment of chronic HCV has been inadequate. So far the standard
therapy of chronic HCV infection is based on a combination of pegylated interferon-α (peg-IFNα)
and ribavirin (RBV). Although this combination can lead to a sustained virologic response (SVR),
it does not prevent future reinfection and is less efficacious in patients with advanced disease [16].
The introduction of direct-acting antiviral drugs (DAAs)—with the two first-generation protease
inhibitors (PI), boceprevir and telaprevir—has increased the number of patients who respond to
treatment [17]. In the present study, we examined a panel of MMPs and TIMPs in plasma samples from
HCV monoinfected patients and HIV/HCV coinfected patients under effective antiretroviral therapy.
We also assessed the dynamic changes of MMPs and TIMPs in HCV monoinfected patients receiving
dual therapy with peg-IFNα and RBV (PR) or triple anti-HCV therapy with PR plus first-generation
HCV NS3/4A protease inhibitors (telaprevir or boceprevir).
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2. Results
2.1. Detection of Different Matrix Metalloproteinase (MMP) and Tissue Inhibitors of Metalloproteinase
(TIMP) Levels in Plasma of Hepatitis C Virus (HCV) Monoinfected, HIV/HCV Coinfected Subjects, and
Healthy Donors
As reported in Table 1, the immunoassay analysis of plasma from healthy donors (HD), coinfected
HIV/HCV and monoinfected HCV subjects, at time of recruitment, indicated that, with the exception
of MMP-13, all the analyzed MMPs and TIMPs were detectable in the samples of the analyzed subject
categories. In particular, levels of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were significantly
higher in samples from HCV and HIV/HCV patients in comparison with HD.
Table 1. Matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) levels
in plasma samples from healthy donors (HD), plasma of hepatitis C virus (HCV) monoinfected and
HIV/HCV coinfected subjects at baseline.
Enzyme or Inhibitor HD HCV/HIV HCV
MMP-1 (ng/mL) 3.5 (0.2–11) 26 (7.6–56) *** 20.5 (0.8–37) ***
MMP-2 (ng/mL) 96.7 (54–163.4) 185 (77–231) ** 183 (80–274) **
MMP-3 (ng/mL) 1 (1–3.5) 1 (3.9–1.14) 1 (1–20)
MMP-8 (ng/mL) 8.3 (1.5–66) 15.3 (4.6–147) 18 (1.6–49.4)
MMP-9 (ng/mL) 171 (107–403) 685 (260–1707) *** 295 (137–1000) *
MMP-10 (ng/mL) 0.02 (0.2–2.9) 1.1 (0.02–8) 1.1 (0.02–4.4)
TIMP-1 (ng/mL) 79 (43–135) 130.6 (62–198) * 124 (63.3–230) *
TIMP-2 (ng/mL) 161 (139–200) 232 (162–262) *** 220 (119–300) **
Data represent the median and the range values. Values significantly different in comparison to HD are
indicated by asterisks (one-way ANOVA followed by Tukey’s Multiple Comparison Test; * p < 0.05, ** p < 0.01,
and *** p < 0.001).
2.2. Plasma Levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Different Groups Analyzed
Figure 1 shows the distribution of MMP-2 and MMP-9, which were the highest expressed MMPs,
as well as of TIMP-1 and TIMP-2, in plasma samples from subjects of the different categories analyzed.
A statistically significant increase of MMP-2, MMP-9, TIMP-1, and TIMP-2 levels was detected in
HCV monoinfected and HIV/HCV coinfected subjects compared to HD. Levels of MMP-2, TIMP-1,
and TIMP-2 were comparable in HCV and HIV/HCV subjects, whereas a statistically significant
increase of MMP-9 levels was found in HIV/HCV coinfected subjects in comparison with HCV
monoinfected subjects.
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monoinfected subjects. The quantification of MMPs and TIMPs in the samples was determined using 
a calibration curve obtained by known concentrations of MMPs and TIMPs standard. The reported 
scatter plots show the distribution of MMP-2, MMP-9, TIMP-1, and TIMP-2 levels, expressed as 
ng/mL, in the plasma of the different analyzed categories. Horizontal bars indicate the median and 
asterisks represent values statistically different among the analyzed categories (* p < 0.05; ** p < 0.01; 
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Figure 1. Distribution of MMP-2 (MMP, matrix metalloproteinase), MMP-9, TIMP-1 (TIMP, tissue
inhibitors of metalloproteinase), and TIMP-2 levels in plasma from healthy donors, HIV/HCV
coinfected, and HCV monoinfected subjects. MMP-9 (A), TIMP-1 (B), MMP-2 (C), and TIMP-2 (D)
were detected at baseline in plasma from healthy donors (HD), HIV/HCV coinfected, and HCV
monoinfected subjects. The quantification of MMPs and TIMPs in the samples was determined using
a calibration curve obtained by known concentrations of MMPs and TIMPs standard. The reported
scatter plots show the distribution of MMP-2, MMP-9, TIMP-1, and TIMP-2 levels, expressed as ng/mL,
in the plasma of the different analyzed categories. Horizontal bars indicate the median and asterisks
represent values statistically different among the analyzed categories (* p < 0.05; ** p < 0.01; *** p < 0.001)
(one-way Anova followed by the post hoc Tukey’s Multiple Comparison Test).
2.3. Correlation between Liver Stiffness and TIMP-1 Levels in HCV Monoinfected and HIV/HCV
Coinfected Subjects
As shown in Figure 2, a statistically significant correlation was found in HCV monoinfected
(Figure 2A) and HIV/HCV coinfected subjects (Figure 2B) between TIMP-1 plasma levels and liver
stiffness at time of recruitment, indicating the existence of a relationship between TIMP-1 and liver
fibrosis. The receiver operating characteristic (ROC) curve of plasma TIMP-1 levels, which represents
the relationship between the sensitivity and the specificity of plasma TIMP-1 in detecting liver fibrosis,
showed that a cutoff value of 89 ng/mL resulted in 91.67% sensitivity and 83.33% specificity for HCV
monoinfected and 100% sensitivity and 84.43% specificity for HIV/HVC coinfected patients
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in HCV monoinfected subjects in comparison with HIV/HCV coinfected subjects. These findings are
consistent with the degree of liver fibrosis, which in our study population was more severe in HCV
monoinfected patients when compared with HIV/HCV coinfected patients (Figure 3B).
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subjects. The histograms in Figure 3A represent the ratio between TIMP-1 and MMP-9 levels detected at
baseline (T0) in plasma from HIV/HCV coinfected and HCV monoinfected subjects; The histograms in
Figure 3B represent the degree of liver stiffness calculated by ultrasound based transient elastography
using FibroScan. Asterisks represent values statistically different among the analyzed categories
(** p < 0.01) (Student’s t-test).
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In particular, the plasma levels of MMPs and TIMPs were assessed in the HCV-infected patients at
time of recruitment (T0, baseline) and after 1 (T1), 6 (T2), and 12 (T3) months of treatment.
As shown in Figures 4 and 5 at baseline no differences were detected in the levels of P-2,
TI P-1, and TIMP-2 between subjects treated with dual or triple therapy. In contrast, MMP-9 baseline
levels were highest in the subjects that had been treated with triple therapy in comparison with those
subjected to dual therapy. However, the longitudinal study highlighted that both therapies reduced
MMP-9 levels (40% reduction) in comparison with their respective baseline levels, whereas they had
no effect on MMP-2, TIMP-1, and TIMP-2. In particular, a significant decrease of MMP-9 levels was
reported in the first month of dual anti-HCV therapy, followed by a gradual increase until the 12th
month. Conversely, triple anti-HCV therapy induced a statistically significant reduction of MMP-9
levels that remained constant during the entire treatment period.
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Figure 4. Longitudinal evaluation of MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in plasma from
HCV monoinfected individuals subjected to dual therapy. The box plots in Figure 4 represent levels
(ng/mL) of MMP-9 (A), MMP-2 (B), TIMP-1 (C), and TIMP-2 (D) in plasma from HCV monoinfected
subjects at the time of recruitment (T0, baseline) and after 3 (T1), 6 (T2), and 12 (T3) months of treatment
with dual anti-HCV therapy with pegylated interferon-α (peg-IFNα) and ribavirin (RBV). Horizontal
bars indicate the medians. Asterisks represent values statistically different from baseline (* p < 0.05;
** p < 0.01) (one-way Anova followed by the post hoc Tukey’s Multiple Comparison Test).
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Figure 5. Longitudinal study on the effect of triple therapy on MMP-2, MMP-9, TIMP-1, and TIMP-2
in plasma from HCV monoinfected subjects. The box plots in Figure 5 represent levels (ng/mL) of
MMP-9 (A), MMP-2 (B), TIMP-1 (C) and TIMP-2 (D) in plasma from HCV monoinfected subjects at
the time of recruitment (T0, baseline) and after 3 (T1), 6 (T2), and 12 (T3) months of treatment with
triple anti-HCV therapy with pegylated interferon-α (peg-IFNα) and ribavirin (RBV) + HCV NS3/4A
protease inhibitors (telaprevir or boceprevir). Horizontal bars indicate the medians. Asterisks represent
values statistically different from baseline (* p < 0.05; ** p < 0.01) (one-way Anova followed by the
post hoc Tukey’s Multiple Comparison Test).
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3. Discussion
Although dysregulation of MMPs and TIMPs has been observed in the course of HCV
infection [18–20], a more detailed analysis of the pattern of these enzymes and their inhibitors is
needed to clarify the role of MMPs and TIMPs in the development of liver fibrosis in the course of
HCV monoinfection and HIV/HCV coinfection.
In this study, we analyzed an extensive panel of circulating MMPs and observed an increase of
plasma levels of MMP-1 (collagenase-1), MMP-2 (gelatinase A), and MMP-9 (gelatinase B) in HCV
and HIV/HCV subjects in comparison to HD. Among the studied MMPs we focused our attention
on MMP-2 and MMP-9 for two different reasons: (i) they were the highest expressed MMPs among
those analyzed; (ii) in the family of MMPs, MMP-2 and MMP-9 are particularly important for the
development of liver fibrosis since they degrade type IV collagen (basal membrane) and therefore are
involved in the early steps of tissue remodeling that characterizes chronic liver disease [21,22]. In this
study, we found that MMP-9 plasma concentrations significantly increased in HIV/HCV coinfected
subjects compared to HCV monoinfected subjects, despite the fact that HIV/HCV coinfected subjects
were treated with antiretroviral therapies, which are known to inhibit MMP-9 levels [23,24]. To explain
this result, we suggest that in HIV/HCV coinfected subjects antiretroviral therapy is not able to
counteract the persistent chronic inflammatory state amplified by the synergic effect of the two viruses.
In this study we also found an increase of TIMP-1 and TIMP-2 levels in both HIV/HCV coinfected
and HCV monoinfected subjects, without significant differences between the two groups. In HCV
monoinfected as well as in HIV/HCV coinfected patients, plasma TIMP-1 levels were correlated with
stiffness and discriminated between patients with and without liver fibrosis with both high sensitivity
and specificity, raising the possibility of using circulating TIMP-1 as a non-invasive marker of liver
fibrosis not only in HCV infection [18,25] but also in HIV/HCV coinfection [26]. The balance between
MMPs and TIMPs is a key regulatory factor in vivo since it allows us to determine the net activity of
MMPs and regulate their action in both pathological and physiological conditions. MMPs are known
to degrade the components of the extracellular matrix (ECM), therefore an increased production of
MMPs has been implicated in tissue damage. By contrast, an excess of TIMP production may be
associated with ECM apposition. Therefore, it is important to determine not only the levels of the
isolated enzymes or inhibitors, but also the ratio of enzyme to inhibitor. In our experiments we found a
significant increase in the ratio TIMP-1/MMP-9 in HCV monoinfected in comparison with HIV/HCV
coinfected subjects. This imbalance toward TIMP-1 may justify the highest levels of stiffness in HCV
monoinfected individuals, suggesting that the TIMP-1/MMP-9 ratio mirrors the progression of hepatic
fibrosis better than TIMP-1 levels.
In our study we found a lower degree of liver stiffness in our population of HIV/HCV coinfected
patients in comparison to the HCV monoinfected subjects. Before the advent of ART, cirrhosis
progression was more frequent in HIV/HCV coinfection than in HCV monoinfection [27,28]. In
addition, fibrosis progression and the clinical progression to liver decompensation or death were
shown to be accelerated in HIV/HCV coinfected patients [29] with advanced immunodeficiency [30].
By contrast, slower fibrosis progression [31] and reduced liver-related mortality were observed in
HIV/HCV coinfected patients treated with ART [32]. In addition, a recent study showed a reduction
in liver fibrosis scores in HIV-coinfected subjects after 48 weeks of ART treatment [33]. Therefore,
although other factors such as heavy alcohol consumption or the duration of HCV infection may be
associated with the progression of liver fibrosis, we cannot exclude the possibility that the lower degree
of liver stiffness found in our population of HIV/HCV coinfected patients could be due to the effect of
ART treatment.
Until 2011, the standard of care for management of chronic HCV hepatitis was the combination
of dual therapy with pegylated interferon-α plus ribavirin (PR). More recently, the landscape for the
therapy of HCV infection has dramatically changed with the advent of direct-acting antiviral agents
(DAAs) [17].
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In the present study, we longitudinally assessed the levels of MMPs and TIMPs in HCV
monoinfected patients receiving dual PR therapy or triple therapy including PR + first generation HCV
protease inhibitors telaprevir or boceprevir. A rapid decline of MMP-9 levels was already evident in
the first month of both treatments, suggesting that such therapies may mediate the tissue remodeling
and liver inflammation associated with HCV-infection, through their effect on MMP-9 levels. However,
the triple therapy was more effective since the MMP-9 levels remained persistently low until the end
of treatment. Therefore, the benefits yielded by the HCV protease inhibitors may be ascribed not only
to the suppression of virus replication but also to other extravirologic effects. In previous studies, we
demonstrated that antiretroviral protease inhibitors have the capability to directly inhibit MMP-2 and
MMP-9 secretion and expression in lipopolysaccharide (LPS)-activated glial cells [23]. In addition, HIV
protease inhibitors are able to significantly downregulate the expression of MMP-9 in mononuclear
cells from HIV-infected individuals [24]. Based on these findings, we can hypothesize that HCV
protease inhibitors could also downregulate MMPs with mechanisms that are independent from their
capability to block HCV replication. Future studies with newer interferon-free and ribavirin-free
regimens could give more information on the dynamic changes of MMPs and TIMPs during treatment
and their correlation with virologic response to treatment also in HIV/HCV coinfected patients.
4. Materials and Methods
4.1. Study Design
We assessed 83 plasma samples from 16 HCV monoinfected subjects and 15 HIV/HCV
coinfected subjects recruited from the Infectious Diseases Unit, Sapienza University, Latina, Italy.
The HCV-infected patients, at time of recruitment, had never been treated with anti-HCV drugs and
started therapy when they were enrolled in the study, after the first collection of blood. Of these
patients, eight were treated with dual anti-HCV therapy with pegylated interferon-α (peg-IFNα) and
ribavirin (RBV) (PR), whereas eight were treated with triple therapy including PR + HCV NS3/4A
protease inhibitors telaprevir or boceprevir. HCV-treated patients were monitored after 1 (T1), 6 (T2),
and 12 (T3) months from the beginning of the therapy. The degree of liver stiffness was calculated by
ultrasound-based transient elastography using FibroScan. The 15 subjects coinfected with HCV and
HIV were receiving antiretroviral therapy and had plasma HIV-RNA plasma levels <20 copies/mL.
The control group included 14 healthy donors (HD) who did not show symptoms of viral infection
at least 15 days before and after blood donation. The demographic and clinical characteristics of
HIV/HCV and HCV subjects and HD as well as the biochemical parameters at baseline are reported
in Table 2.
4.2. Detection of MMP and TIMP Levels in Plasma Samples
The circulating plasma levels of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, MMP-13,
TIMP-1, and TIMP-2 were assessed by the SearchLight Multiplex Immunoassay Kits (Aushon
BioSystems, Billerica, MA, USA) according to the manufacturer’s instructions. This Immunoassay Kit
is a multiplex antibody array that measures multiple proteins simultaneously within a single sample
increasing sensitivity over the uniplex enzyme immunoassays like Elisa. For the analysis the plasma
was diluted 1:100 with the provided diluent. The quantification of MMPs and TIMPs in the samples
was determined using a calibration curve obtained using known concentrations of standards.
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Table 2. Demographic and clinical parameters of healthy donors (HD), HCV monoinfected, and HIV/HCV coinfected subjects.
Parameters HD (n = 12) HCV (n = 16) HIV/HCV (n = 15) p Value
Age, Years 46 (28–56) 46 (24´66) 53 (47´57) 0.02 a
Male/Female (% male) 3/9 (25%) 11/5 (68%) 7/8 (46%) 0.07 b
Liver Stiffness (kPa) – 10 (6.1´35.8) 6.1 (4.3´29.5) 0.03 c
ALT (UI/L) – 98 (40´450) 58 (24´115) 0.09 c
AST (UI/L) – 65.5 (27´141) 43 (24´79) 0.24 c
GGT (UI/L) – 48.5 (17´134) 44 (20´665) 0.9 c
PLT (109/L) – 168 (89´385) 167 (89´332) 0.06 c
Tot BIL (mg/dL) – 0.64 (0.38´1.12) 0.8 (0.39´4.3) 0.39 c
HCV-RNA (copies ˆ 106/mL) NA 2.72 (0.3´11) 1.13 (0.06´16.5) 0.090 c
HIV-RNA (copies/mL) NA NA <20 NA
Results are expressed as median (range). p values were calculated by using the a Kruskal–Wallis test, the b χ-Square test, or the c Mann–Whitney test. ALT: Alanine aminotransferase;
AST: Aspartate aminotransferase; GGT: gamma glutamiltranspepsidasi; PLT: Platelet; Tot BIL: total bilirubin; NA: not analyzed.
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4.3. Statistical Analysis
Parametric one-way analysis of variance, ANOVA, or the non-parametric Kruskal–Wallis test
were used to compare the three groups of healthy controls (HD), HCV monoinfected, and HIV/HCV
coinfected subjects, as appropriate. In cases of statistical significance, the parametric Tukey’s Multiple
Comparison post hoc test or the non-parametric Mann–Whitney test was used for the pair-wise
comparison of groups. The χ-Square was used for comparison of gender percentages. Student’s
T-test was used to compare TIMP-1/MMP-9 ratio and liver stiffness in HCV monoinfected and
HIV/HCV coinfected subjects.
The correlation between liver stiffness and TIMP-1 levels in HCV monoinfected and HIV/HCV
coinfected subjects was performed using the Pearson’s correlation coefficient. Reported P values were
considered statistically significant at p < 0.05.
Data were analyzed by the GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).
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